May 17 (Reuters) - AstraZeneca ( AZN ) owes Pfizer ( PFE )

$107.5 million in damages, a Delaware federal jury said

on Friday after finding that AstraZeneca's ( AZN ) blockbuster lung

cancer drug Tagrisso violated its Wyeth unit's patent rights.

The jury agreed that AstraZeneca's ( AZN ) drug infringed two

patents covering methods for treating cancer with the

breast-cancer drug Nerlynx, which is sold by Puma Biotechnology ( PBYI )

. Puma licenses the patents from Pfizer ( PFE ) to make its

drug.

An AstraZeneca ( AZN ) spokesperson said the company was

disappointed with the verdict but is "confident in our IP

(intellectual property) position in relation to Tagrisso" and

will "vigorously defend" its rights.

Representatives for Pfizer ( PFE ) did not immediately respond to a

request for comment on the verdict. Puma is no longer a

plaintiff in the case.

Tagrisso earned AstraZeneca ( AZN ) nearly $5.8 billion in revenue

last year, according to a company report.

New York-based Pfizer ( PFE ), which acquired Wyeth in 2009, sued

AstraZeneca ( AZN ) in 2021. It argued that Tagrisso used kinase

inhibitors to treat cancer in the same way as Nerlynx.

AstraZeneca ( AZN ) denied infringing the patents and argued that

they are invalid.

U.S. District Judge Matthew Kennelly will hold a separate

bench trial on some of AstraZeneca's ( AZN ) remaining defenses in June,

which could result in a ruling that negates the verdict.